Which is the best statin for the postoperative coronary artery bypass graft patient?

Area of Science:

• Cardiology
• Pharmacology
• Atherosclerosis Research

Background:

• Atherosclerosis progression post-coronary artery bypass graft (CABG) necessitates re-vascularization in many patients.
• Controlling low-density lipid cholesterol (LDL-C) with statins is crucial for mitigating this risk.

Purpose of the Study:

• To review lipid-lowering therapy rationale in post-CABG patients.
• To objectively compare statin effectiveness, cost, and tolerability in the post-CABG setting.

Main Methods:

• Comparative analysis of statin efficacy based on LDL-C reduction and target achievement.
• Review of 'real-world' observational studies on statin performance.
• Consideration of high-density lipid cholesterol (HDL-C) increase and anti-atherogenic properties.

Main Results:

• Rosuvastatin demonstrates superior LDL-C reduction and higher achievement of LDL-C targets compared to simvastatin and atorvastatin at equivalent doses.
• Rosuvastatin's effectiveness in reaching LDL-C targets is confirmed in real-world studies.
• Rosuvastatin shows a greater increase in HDL-C compared to other statins, enhancing anti-atherogenic effects.

Conclusions:

• Rosuvastatin is the most effective statin for post-CABG patients regarding LDL-C reduction and target attainment.
• The choice of statin should consider effectiveness, cost, and tolerability, not just generic availability.
• Rosuvastatin offers significant anti-atherogenic benefits due to its impact on both LDL-C and HDL-C levels.